Presentation and survival by hormonal receptor status in metaplastic breast cancer: A propensity score-matched analysis
Background: Metaplastic breast cancer (MBC) is a rare and aggressive form of breast cancer. The effectiveness of chemotherapy (CT) for MBC remains controversial. The present study aimed to evaluate the efficacy of CT combined hormone receptor (HR) status on MBC patients with high risk (T1-4N2-3M0 an...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977621009747 |
| _version_ | 1831758964795113472 |
|---|---|
| author | Siqin Wang Jin Hu Yanting Zhang Jian Shen Fang Dong Ximeng Zhang Chong Lu Dan Shang |
| author_facet | Siqin Wang Jin Hu Yanting Zhang Jian Shen Fang Dong Ximeng Zhang Chong Lu Dan Shang |
| author_sort | Siqin Wang |
| collection | DOAJ |
| description | Background: Metaplastic breast cancer (MBC) is a rare and aggressive form of breast cancer. The effectiveness of chemotherapy (CT) for MBC remains controversial. The present study aimed to evaluate the efficacy of CT combined hormone receptor (HR) status on MBC patients with high risk (T1-4N2-3M0 and T4N0-1M0) by propensity-score matching (PSM). Methods: A retrospective study was performed to analyze MBC from the SEER database. Breast cancer-specific survival (BCSS) was analyzed using the Kaplan–Meier curve. Cox proportional hazard models were used to assess BCSS. PSM was used to make 1:1 case-control matching. Results: This study identified 3116 patients. The median follow-up time was 44 months (range, 1–321 months). About 62.5 % of patients received CT. 23.0 % of patients were HR-positive. Recurrence risk had a significant difference between the HR-negative and HR-positive groups. In the multivariable Cox regression model, CT had no benefit for MBC patients. HR status was not associated with a better prognosis. In subgroup analysis, the Kaplan–Meier analysis showed that HR-negative MBC with intermediate-risk benefited from CT. For HR-positive MBC, patients with intermediate and high risk also benefited from CT. After PSM, neither CT nor HR status was not related to better BCSS. Moreover, the use of CT could only improve the survival of HR-positive MBC patients with high risk. Conclusion: PSM analysis showed that HR status was not associated with a better prognosis. CT was not a significant prognostic factor for prognosis. However, HR-positive MBC patients with high risk might benefit from CT. |
| first_indexed | 2024-12-22T00:58:46Z |
| format | Article |
| id | doaj.art-c1ac1dbdd84c4d5986c3ea1325b871cd |
| institution | Directory Open Access Journal |
| issn | 1532-3080 |
| language | English |
| last_indexed | 2024-12-22T00:58:46Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj.art-c1ac1dbdd84c4d5986c3ea1325b871cd2022-12-21T18:44:15ZengElsevierBreast1532-30802021-12-0160168176Presentation and survival by hormonal receptor status in metaplastic breast cancer: A propensity score-matched analysisSiqin Wang0Jin Hu1Yanting Zhang2Jian Shen3Fang Dong4Ximeng Zhang5Chong Lu6Dan Shang7Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, ChinaDepartment of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, ChinaDepartment of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; Corresponding author.Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; Corresponding author. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei Province, 430022, China.Background: Metaplastic breast cancer (MBC) is a rare and aggressive form of breast cancer. The effectiveness of chemotherapy (CT) for MBC remains controversial. The present study aimed to evaluate the efficacy of CT combined hormone receptor (HR) status on MBC patients with high risk (T1-4N2-3M0 and T4N0-1M0) by propensity-score matching (PSM). Methods: A retrospective study was performed to analyze MBC from the SEER database. Breast cancer-specific survival (BCSS) was analyzed using the Kaplan–Meier curve. Cox proportional hazard models were used to assess BCSS. PSM was used to make 1:1 case-control matching. Results: This study identified 3116 patients. The median follow-up time was 44 months (range, 1–321 months). About 62.5 % of patients received CT. 23.0 % of patients were HR-positive. Recurrence risk had a significant difference between the HR-negative and HR-positive groups. In the multivariable Cox regression model, CT had no benefit for MBC patients. HR status was not associated with a better prognosis. In subgroup analysis, the Kaplan–Meier analysis showed that HR-negative MBC with intermediate-risk benefited from CT. For HR-positive MBC, patients with intermediate and high risk also benefited from CT. After PSM, neither CT nor HR status was not related to better BCSS. Moreover, the use of CT could only improve the survival of HR-positive MBC patients with high risk. Conclusion: PSM analysis showed that HR status was not associated with a better prognosis. CT was not a significant prognostic factor for prognosis. However, HR-positive MBC patients with high risk might benefit from CT.http://www.sciencedirect.com/science/article/pii/S0960977621009747MetaplasticBreast cancerHormonal receptor statusChemotherapyPropensity score-matched |
| spellingShingle | Siqin Wang Jin Hu Yanting Zhang Jian Shen Fang Dong Ximeng Zhang Chong Lu Dan Shang Presentation and survival by hormonal receptor status in metaplastic breast cancer: A propensity score-matched analysis Breast Metaplastic Breast cancer Hormonal receptor status Chemotherapy Propensity score-matched |
| title | Presentation and survival by hormonal receptor status in metaplastic breast cancer: A propensity score-matched analysis |
| title_full | Presentation and survival by hormonal receptor status in metaplastic breast cancer: A propensity score-matched analysis |
| title_fullStr | Presentation and survival by hormonal receptor status in metaplastic breast cancer: A propensity score-matched analysis |
| title_full_unstemmed | Presentation and survival by hormonal receptor status in metaplastic breast cancer: A propensity score-matched analysis |
| title_short | Presentation and survival by hormonal receptor status in metaplastic breast cancer: A propensity score-matched analysis |
| title_sort | presentation and survival by hormonal receptor status in metaplastic breast cancer a propensity score matched analysis |
| topic | Metaplastic Breast cancer Hormonal receptor status Chemotherapy Propensity score-matched |
| url | http://www.sciencedirect.com/science/article/pii/S0960977621009747 |
| work_keys_str_mv | AT siqinwang presentationandsurvivalbyhormonalreceptorstatusinmetaplasticbreastcancerapropensityscorematchedanalysis AT jinhu presentationandsurvivalbyhormonalreceptorstatusinmetaplasticbreastcancerapropensityscorematchedanalysis AT yantingzhang presentationandsurvivalbyhormonalreceptorstatusinmetaplasticbreastcancerapropensityscorematchedanalysis AT jianshen presentationandsurvivalbyhormonalreceptorstatusinmetaplasticbreastcancerapropensityscorematchedanalysis AT fangdong presentationandsurvivalbyhormonalreceptorstatusinmetaplasticbreastcancerapropensityscorematchedanalysis AT ximengzhang presentationandsurvivalbyhormonalreceptorstatusinmetaplasticbreastcancerapropensityscorematchedanalysis AT chonglu presentationandsurvivalbyhormonalreceptorstatusinmetaplasticbreastcancerapropensityscorematchedanalysis AT danshang presentationandsurvivalbyhormonalreceptorstatusinmetaplasticbreastcancerapropensityscorematchedanalysis |